The Brief

Researchers at the University of Gothenburg have identified two gut bacterial species — Limosilactobacillus mucosae and Ligilactobacillus ruminis — that directly produce bioactive serotonin, a first in microbiome research. When introduced to serotonin-deficient mice, the bacterial pair restored gut serotonin levels, increased colonic nerve density, and normalised intestinal transit time. The study, published in Cell Reports, also found that IBS patients carry significantly lower levels of one of the species.

The Report

A team of 24 researchers across Sweden, the United States, Switzerland, and Denmark has demonstrated that two species of lactobacilli can synthesise bioactive serotonin in the gut — not merely stimulate the host to produce more of it, as prior research had shown, but manufacture the molecule themselves.

The study, led by Chiara Moretti and corresponding author Fredrik Bäckhed at the University of Gothenburg’s Wallenberg Laboratory, found that Limosilactobacillus mucosae and Ligilactobacillus ruminis work cooperatively to convert 5-hydroxytryptophan into serotonin through decarboxylation. Neither bacterium produces serotonin alone. When both were introduced to germ-free mice with serotonin deficiency, the consortium increased intestinal serotonin levels, expanded nerve cell density in the colon, and normalised transit time to match that of conventionally colonised animals.

The distinction from earlier work is significant. A landmark 2015 study from Caltech established that spore-forming gut bacteria influence the host’s own serotonin production in enterochromaffin cells — the intestinal cells responsible for generating more than 90 percent of the body’s serotonin supply. The Gothenburg finding represents a different mechanism entirely: the bacteria themselves are the factory.

The researchers tested 147 patients with irritable bowel syndrome and found significantly reduced abundance of L. mucosae compared to healthy controls. The reduction correlated specifically with harder stools. IBS, the most prevalent disorder of gut-brain interaction, affects an estimated 5 to 10 percent of the global population, with women roughly 1.7 times more susceptible than men.

“Our results indicate that certain intestinal bacteria can produce bioactive serotonin and thus play an important role in intestinal health,” said Magnus Simrén, professor of medical gastroenterology at Sahlgrenska Academy, adding that the findings “open new avenues for the treatment of functional gastrointestinal disorders such as IBS.”

The study carries notable limitations. The serotonin effect was local — confined to the colon — with serum levels unchanged, suggesting no direct systemic or neurological impact. The germ-free mouse model, while useful for isolating bacterial effects, does not replicate the complexity of an established human microbiome. The mechanistic regulators governing microbial serotonin synthesis remain unresolved.

BioGaia AB, a publicly traded Swedish probiotic company that partnered on the research, has signalled commercial interest. Chief Scientific Officer Gianfranco Grompone described the findings as opening “the way for development of innovative probiotic products in the gut health and mental health spaces.” The study was published in Cell Reports in October 2025, with renewed press attention following a March 2026 release.

The Angle

The finding that bacteria produce serotonin themselves — rather than coaxing the host into producing more — is the kind of mechanistic shift that tends to age well. It moves the microbiome from a system that modulates human biology to one that runs parallel biochemistry alongside it. The body is not merely influenced by its inhabitants. It is, in specific and measurable ways, chemically co-authored by them.

What makes this worth watching is less the IBS application — real but incremental — than what the cooperative requirement implies. Two species, neither functional alone, performing a synthesis step that the host’s own cells also perform independently. The gut has redundant serotonin infrastructure, some of it human, some of it bacterial, operating through different pathways toward the same molecule. That is not a symbiosis anyone designed. It is an arrangement that emerged because it worked, and it has been invisible until now because no one had isolated the mechanism from the noise.

The commercial trajectory is already visible — BioGaia’s press release appeared the same day as the paper. Probiotic products targeting serotonin production will arrive well before the underlying biology is fully mapped. That gap between what can be sold and what is understood is where most microbiome science currently lives. The research itself is careful about what it claims. Whether the market will be equally careful is a different question, and the answer is already legible in the language of the press release.